Live Breaking News & Updates on பேட்ரிக் சீதம்|Page 5
Stay updated with breaking news from பேட்ரிக் சீதம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate |Tertiary Minerals Announcements | Tertiary Minerals: Kalkkinen Project investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
The Company is pleased to advise that it has appointed Mr. James Cole as an independent non-executive director ( NED ) of the Company with immediate effect. Mr. Cole will replace Mr. David Swan on the Board, who is stepping down from his role.
Mr Swan has served as a NED of the Company for nine years, a period which is encouraged as a maximum term under the UK Corporate Governance Code ( the Code ) to safeguard the independence of a NED. Whilst the Company follows the QCA Corporate Governance Code, which allows for a more pragmatic view on the independence of NEDs, the Company respects Mr Swan s decision to apply this part of the Code to his time in office. ....
Oxford Biomedica shares surge after it raises its forecast for COVID-19 vaccine revenues A look at the major movers on the London market on Tuesday Oxford Biomedica PLC (LON:OXB) has been boosted by vaccine news. The company, a key manufacturer of the Oxford/AstraZeneca PLC (LON:AZN) COVID-19 vaccine, has doubled its expectations for revenue from the contract. The gene and cell therapy group said AstraZeneca had increased the number of batches required for the jab in the second half. It now estimates its revenues from the vaccine will be £100mln, up from previous forecasts of £50mln. The company s shares have jumped 128p or 12.77% to 1130p, making it the biggest riser in the FTSE 350. ....
Oxford Biomedica shares surge after it raises its forecast for COVID-19 vaccine revenues A look at the major movers on the London market on Tuesday Oxford Biomedica PLC (LON:OXB) has been boosted by vaccine news. The company, a key manufacturer of the Oxford/AstraZeneca PLC (LON:AZN) COVID-19 vaccine, has doubled its expectations for revenue from the contract. The gene and cell therapy group said AstraZeneca had increased the number of batches required for the jab in the second half. It now estimates its revenues from the vaccine will be £100mln, up from previous forecasts of £50mln. The company s shares have jumped 128p or 12.77% to 1130p, making it the biggest riser in the FTSE 350. ....